Ozempic Gastroparesis Attorney: Understanding the Statute of Limitations in Illinois

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Exposure Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context emphasized broad awareness of wellness principles and the importance of informed decision-making in healthcare. Within this framework, discussions around metabolic health and diabetes management have evolved significantly, introducing new therapeutic agents that require careful consideration of their broader implications. As the landscape of pharmaceutical interventions expands, attention has naturally shifted from general health education to specific exposure scenarios. One such area of growing focus involves the use of glucagon-like peptide-1 receptor agonists, including medications like Ozempic, which have been widely adopted for glycemic control and weight management. This transition from general health discourse to targeted therapeutic exposure brings into focus the need to examine potential adverse outcomes associated with long-term use.

Bridging to Ozempic and Gastroparesis

In particular, the relationship between these medications and gastrointestinal motility has emerged as a point of clinical and legal interest. The concern now moves from abstract health information to concrete occupational and personal exposure contexts, where individuals may face prolonged contact with these agents. This pivot underscores the importance of understanding how sustained exposure, whether through direct administration or environmental contact in healthcare settings, may correlate with conditions such as gastroparesis. The following discussion will explore these exposure dynamics without venturing into mechanistic claims, maintaining a neutral academic perspective on the evolving intersection of pharmaceutical use and patient safety.

Clinical Evidence Linking Ozempic to Gastrointestinal Adverse Reactions

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action slows gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, abdominal pain, and early satiety. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests. The overlap between Ozempic's known gastrointestinal effects and gastroparesis symptoms raises questions about a causal link. Clinical trial data from the Ozempic prescribing information document a significantly higher incidence of gastrointestinal adverse reactions compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for 0.5 mg and 3.8% for 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in at least 5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which are core features of gastroparesis.

Mechanistic Plausibility and Warning Adequacy

Mechanistically, GLP-1 receptor agonists like Ozempic inhibit gastric motility and slow gastric emptying. This pharmacodynamic effect is intended to reduce postprandial glucose excursions but can lead to prolonged gastric retention. In susceptible individuals, this may precipitate or exacerbate gastroparesis. The reported adverse reactions—nausea, vomiting, abdominal pain, and constipation—align with the clinical presentation of gastroparesis. While the prescribing information does not explicitly list gastroparesis as an adverse reaction, the high frequency of these symptoms suggests a plausible pathway. The label notes that in a 40-week trial with 959 patients treated with Ozempic 1 mg or 2 mg as add-on to metformin with or without sulfonylurea, no new safety signals were identified (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, this does not exclude the possibility of gastroparesis occurring in a subset of patients, especially those with pre-existing gastrointestinal conditions or prolonged exposure. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a key consideration. The prescribing information warns of serious hypersensitivity reactions, including anaphylaxis and angioedema, and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, it does not specifically warn about gastroparesis. This gap may be relevant for patients who develop persistent gastrointestinal symptoms after starting Ozempic.

Legal Considerations and Illinois Statute of Limitations

For affected patients, attorney-related considerations include evaluating whether the manufacturer provided adequate warnings about the risk of severe gastrointestinal complications, including gastroparesis. The timeline between exposure and documented harm is also critical. In clinical trials, gastrointestinal adverse reactions were most common during dose escalation, but symptoms can persist or worsen over time. Patients who experience prolonged nausea, vomiting, or abdominal pain after months of Ozempic use may have a stronger case for causation. In Illinois, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For gastroparesis allegedly caused by Ozempic, this means patients must file a claim within two years of recognizing that their symptoms are linked to the medication. Given that gastrointestinal symptoms can be gradual, the discovery date may be when a physician diagnoses gastroparesis and identifies Ozempic as a potential cause. Patients should consult an attorney promptly to preserve their legal rights.

Summary of Evidence and Next Steps

In summary, the evidence shows a clear association between Ozempic use and gastrointestinal adverse reactions that mirror gastroparesis symptoms. While the prescribing information does not explicitly warn about gastroparesis, the mechanistic plausibility and clinical trial data support a link. Patients in Illinois who develop gastroparesis after taking Ozempic should be aware of the two-year statute of limitations and seek legal advice to assess their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Illinois?

In Illinois, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For gastroparesis allegedly caused by Ozempic, this means patients must file a claim within two years of recognizing that their symptoms are linked to the medication. The discovery date may be when a physician diagnoses gastroparesis and identifies Ozempic as a potential cause.

Does Ozempic cause gastroparesis?

Clinical trial data show that Ozempic significantly increases the incidence of gastrointestinal adverse reactions such as nausea, vomiting, abdominal pain, and constipation, which are core symptoms of gastroparesis. While the prescribing information does not explicitly list gastroparesis as an adverse reaction, the mechanistic plausibility (slowing of gastric emptying) and high frequency of these symptoms suggest a potential link. Patients experiencing persistent gastrointestinal symptoms should consult their healthcare provider.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.